blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2588451

EP2588451 - PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.11.2016
Database last updated on 15.06.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim / DE
[2013/19]
Inventor(s)01 / ROTH, Gerald Juergen
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
02 / FLECK, Martin
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
03 / LEHMANN-LINTZ, Thorsten
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
04 / NEUBAUER, Heike
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
05 / NOSSE, Bernd
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
 [2016/01]
Former [2013/19]01 / ROTH, Gerald Juergen
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
02 / FLECK, Martin
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
03 / LEHMANN-LINTZ, Thorsten
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
04 / NEUBAUER, Heike
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
05 / NOSSE, Bernd
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Representative(s)Simon, Elke Anna Maria
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2016/01]
Former [2013/19]Simon, Elke Anna Maria
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date11730270.330.06.2011
[2016/01]
WO2011EP61012
Priority number, dateEP2010016811301.07.2010         Original published format: EP 10168113
[2013/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012001107
Date:05.01.2012
Language:EN
[2012/01]
Type: A1 Application with search report 
No.:EP2588451
Date:08.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 05.01.2012 takes the place of the publication of the European patent application.
[2013/19]
Type: B1 Patent specification 
No.:EP2588451
Date:30.12.2015
Language:EN
[2015/53]
Search report(s)International search report - published on:EP05.01.2012
ClassificationIPC:C07D211/34, C07D401/04, C07D401/12, C07D401/14, C07D405/04, C07D405/14, C07D409/04, C07D411/04, C07D411/14, C07D413/04, C07D413/14, C07D417/14, C07D487/04, C07D495/04, C07D498/04
[2013/19]
CPC:
C07D211/34 (EP,KR,US); A61K31/4465 (KR); A61K45/06 (EP,US);
A61P3/00 (EP); A61P3/04 (EP); A61P3/10 (EP);
C07D401/04 (EP,US); C07D401/12 (EP,US); C07D401/14 (EP,US);
C07D405/04 (EP,US); C07D405/12 (KR); C07D405/14 (EP,US);
C07D409/04 (EP,US); C07D411/04 (EP,US); C07D411/14 (EP,US);
C07D413/04 (EP,US); C07D413/14 (EP,US); C07D417/04 (EP,US);
C07D487/04 (EP,US); C07D495/04 (EP,US); C07D498/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/19]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PIPERIDINDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON STOFFWECHSELERKRANKUNGEN[2013/19]
English:PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS[2013/19]
French:DÉRIVÉS DE PIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES[2013/19]
Entry into regional phase01.02.2013National basic fee paid 
01.02.2013Designation fee(s) paid 
01.02.2013Examination fee paid 
Examination procedure27.04.2012Request for preliminary examination filed
International Preliminary Examining Authority: EP
01.02.2013Examination requested  [2013/19]
30.07.2013Amendment by applicant (claims and/or description)
26.02.2014Despatch of a communication from the examining division (Time limit: M06)
30.07.2014Reply to a communication from the examining division
05.09.2014Despatch of a communication from the examining division (Time limit: M02)
14.10.2014Reply to a communication from the examining division
24.03.2015Communication of intention to grant the patent
08.07.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.08.2015Communication of intention to grant the patent
26.10.2015Fee for grant paid
26.10.2015Fee for publishing/printing paid
26.10.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.02.2014
Opposition(s)03.10.2016No opposition filed within time limit [2016/49]
Fees paidRenewal fee
01.07.2013Renewal fee patent year 03
31.03.2014Renewal fee patent year 04
30.06.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.06.2011
AL30.12.2015
AT30.12.2015
BE30.12.2015
BG30.12.2015
CY30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
MK30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
TR30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
LU30.06.2016
MT30.06.2016
[2018/46]
Former [2018/38]HU30.06.2011
AT30.12.2015
BE30.12.2015
BG30.12.2015
CY30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
MK30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
TR30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
LU30.06.2016
MT30.06.2016
Former [2018/31]HU30.06.2011
AT30.12.2015
BE30.12.2015
CY30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
MK30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
TR30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
LU30.06.2016
MT30.06.2016
Former [2018/29]HU30.06.2011
AT30.12.2015
BE30.12.2015
CY30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
MK30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
TR30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
LU30.06.2016
Former [2018/28]HU30.06.2011
AT30.12.2015
BE30.12.2015
CY30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
MK30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
Former [2017/25]AT30.12.2015
BE30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
CH30.06.2016
IE30.06.2016
LI30.06.2016
Former [2017/16]AT30.12.2015
BE30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SI30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
Former [2017/07]AT30.12.2015
BE30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
MC30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
Former [2017/03]AT30.12.2015
BE30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
Former [2016/46]AT30.12.2015
CZ30.12.2015
DK30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
Former [2016/38]AT30.12.2015
CZ30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SK30.12.2015
SM30.12.2015
NO30.03.2016
GR31.03.2016
IS30.04.2016
PT02.05.2016
Former [2016/36]AT30.12.2015
CZ30.12.2015
EE30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
IT30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
PL30.12.2015
RO30.12.2015
RS30.12.2015
SE30.12.2015
SK30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/35]CZ30.12.2015
ES30.12.2015
FI30.12.2015
HR30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/34]CZ30.12.2015
FI30.12.2015
HR30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/30]FI30.12.2015
HR30.12.2015
LT30.12.2015
LV30.12.2015
NL30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/25]FI30.12.2015
HR30.12.2015
LT30.12.2015
LV30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/24]FI30.12.2015
HR30.12.2015
LT30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
GR31.03.2016
Former [2016/23]HR30.12.2015
LT30.12.2015
RS30.12.2015
SE30.12.2015
NO30.03.2016
Former [2016/21]LT30.12.2015
NO30.03.2016
Former [2016/20]LT30.12.2015
Cited inInternational search[X]WO2004037809  (PFIZER LTD [GB], et al) [X] 1-6,9,10,12 * Preparations 61-64; page 55 - page 57 *;
 [X]OA13029  (PFIZER [US]) [X] 1-6,9,10,12 * Preparation 62; page 76 *;
 [X]WO2008110611  (NOVARTIS AG [CH], et al) [X] 1-6,9,10,12 * page 48; compound 126 * * claim 1 *;
 [A]WO2009144555  (PFIZER [US], et al) [A] 1-15* the whole document *;
 [A]  - HAQUE T S ET AL, "Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 20, doi:10.1016/J.BMCL.2009.08.077, ISSN 0960-894X, (20091015), pages 5872 - 5876, (20090826), XP026640590 [A] 1-15 * page 5873; figure 1 * * tables 1, 2, 3; compounds 3a-10m *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2009.08.077
 [A]  - GU YU GUI ET AL, "N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy Derivatives as Acetyl-CoA Carboxylase Inhibitors-Improvement of Cardiovascular and Neurological Liabilities via Structural Modifications", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20070101), vol. 50, no. 5, doi:10.1021/JM070035A, ISSN 0022-2623, pages 1078 - 1082, XP002448589 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm070035a
by applicant   - G. WOLF, NUTRITION REVIEWS, vol. 66, no. 10, pages 597 - 600
    - DB SAVAGE, KF PETERSEN, GI SHULMAN, PHYSIOL REV., (2007), vol. 87, pages 507 - 520
    - D SAGGERSON, ANNU REV NUTR., (2008), vol. 28, pages 253 - 72
    - GD LOPASCHUK, JR USSHER, JS JASWAL, PHARMACOL REV., (2010), vol. 62, pages 237 - 64
    - LA ABU-ELHEIGA, J. LIPID RES., (2009), vol. 50, pages S138 - S143
    - L. TONG, HJ HARWOOD JR., JOURNAL OF CELLULAR BIOCHEMISTRY, (2006), vol. 99, pages 1476 - 1488
    - JW CORBETT, J H J R.HARWOOD, RECENT PAT CARDIOVASC DRUG DISCOV., (200711), vol. 2, no. 3, pages 162 - 80
    - M MUREA, BI FREEDMANN, JS PARKS, PA ANTINOZZI, SC ELBEIN, LM MA, CLIN J AM SOC NEPHROL., (2010), vol. 5, pages 2373 - 9
    - IE SCHAUER, JK SNELL-BERGEON, BC BERGMAN, DM MAAHS, A KRETOWSKI, RH ECKEL, M REWERS, DIABETES, (2011), vol. 60, pages 306 - 14
    - P EBELING, B ESS6N-GUSTAVSSON, JA TUOMINEN, VA KOIVISTO, DIABETOLOGIA, vol. 41, pages 111 - 115
    - KJ NADEAU, JG REGENSTEINER, TA BAUER, MS BROWN, JL DOROSZ, A HULL, P ZEITLER, B DRAZNIN, JEB. REUSCH, J CLIN ENDOCRINOL METAB, (2010), vol. 95, pages 513 - 521
    - C WANG, S RAJPUT, K WATABE, DF LIAO, D CAO, FRONT BIOSCI, (2010), vol. 2, pages 515 - 26
    - OGAWA M, FUKUYAMA H, OUCHI Y, YAMAUCHI H, KIMURA J, J NEUROL SCI., (1996), vol. 139, no. 1, pages 78 - 82
    - ST HENDERSON, NEUROTHERAPEUTICS, (2008), vol. 5, pages 470 - 480
    - LC COSTANTINI, LJ BARR, JL VOGEL, ST HENDERSON, BMC NEUROSCI., (2008), vol. 9, no. 2, page S16
    - KW BARANANO, AL HARTMAN, CURR TREAT OPTIONS NEUROL., (2008), vol. 10, pages 410 - 9
    - MA REGER, ST HENDERSON, C HALE, B CHOLERTON, LD BAKER, GS WATSON, K HYDEA, D CHAPMANA, S CRAFT, NEUROBIOLOGY OF AGING, (2004), vol. 25, pages 311 - 314
    - MUNGER J, BD BENNETT, A PARIKH, XJ FENG, J MCARDLE, HA RABITZ, T SHENK, JD RABINOWITZ., NAT BIOTECHNOL., (2008), vol. 26, pages 1179 - 86
    - ORG. LETT., (1999), vol. 1, pages 1261 - 1262
    - J. ORGANOMET. CHEM., (2003), vol. 677, page 57
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.